Trials / Completed
CompletedNCT00408993
Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 215 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine if duloxetine 60mg up to 120mg daily can work in treating pain from Diabetic Neuropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Duloxetine Hydrochloride | 60 mg every day (QD) (morning or evening), by mouth (PO) |
| DRUG | Placebo | Placebo every day (QD), by mouth (PO) |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2006-12-08
- Last updated
- 2011-07-26
- Results posted
- 2009-06-02
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00408993. Inclusion in this directory is not an endorsement.